AAIC 2025 Abstract
Validating the cortisol hypothesis: Xanamem demonstrates positive clinical effects by lowering CNS cortisol
Trial in peopleInterventions
Abstract
Background: Xanamem TM (Emestedastat) is an oral, selective 11β‐HSD1 inhibitor designed to reduce cortisol production in the brain under development for the treatment of AD.
